PSVT involves episodes of a faster-than-normal heart rate, often with symptoms resembling anxiety attacks, and while uncomfortable, it’s typically not life threatening. Diagnosis of PSVT typically ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Cardamyst (etripamil) is a nose spray that helps treat sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormal heart rhythm where your ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST), a clinical-stage biopharmaceutical company focused on cardiovascular medicines, announced Monday positive results from Phase 3 RAPID clinical trial ...

Even though PSVT doesn’t seem to lead to serious long-term health issues, you should still talk to your doctor. These symptoms could be signs of another health problem. Cells in the upper chambers of ...

MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...